DOCSLIB.ORG

Mccartney, Karen M. (2015)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Mccartney, Karen M. (2015) THE ROLE OF PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA (PPARα) IN THE EFFECT OF PIROXICAM ON COLON CANCER KAREN MARIE McCARTNEY BSc. (Hons), MSc. Thesis submitted to the University of Nottingham for the degree of Doctor of Philosophy April 2015 Abstract Studies with APCMin/+ mice and APCMin/+ PPARα-/- mice were undertaken to investigate whether polyp development in the mouse gut was mediated by PPARα. Additionally, the effect of piroxicam treatment dependency on PPARα was assessed. Results showed the number of polyps in the colon was significantly higher in APCMin/+ PPARα-/- mice than in APCMin/+ mice, whilst in the small bowel the difference was not significant. Analysis of gene expression in the colon with Affymetrix® microarrays demonstrated the largest source of variation was between tumour and normal tissue. Deletion of PPARα had little effect on gene expression in normal tissue but appeared to have more effect in tumour tissue. Ingenuity pathway analysis of these data showed the top biological processes were growth & proliferation and colorectal cancer. Collectively, these data may indicate that deletion of PPARα exacerbates the existing APCMin/+ mutation to promote tumorigenesis in the colon. 95 genes from Affymetrix® microarray data were selected for further analysis on Taqman® low density arrays. There was good correlation of expression levels between the two array types. Expression data of two genes proved particularly interesting; Onecut homeobox 2 (Onecut2) and Apolipoprotein B DNA dC dU - editing enzyme, catalytic polypeptide 3 (Apobec3). Onecut2 was highly up-regulated in tumour tissue. Apobec3 was up-regulated in APCMin/+ PPARα-/- mice only; suggesting expression was mediated via PPARα. There was a striking increase in survival accompanied by a marked reduction in small intestinal polyp numbers in mice of either genotype that received piroxicam. Taqman® low density array analysis of the same 95 genes as previously showed similar expression levels in piroxicam-treated APCMin/+ mice and APCMin/+ PPARα-/- mice. Taken together, these data indicated that the effect of piroxicam treatment was not mediated via PPARα. i Declaration The work in this thesis was performed entirely by myself (unless otherwise stated) and in no way forms part of any other thesis. The work was carried out at the Nottingham Digestive Diseases Centre (NDDC), Queens Medical Centre, University Hospital, Nottingham, and the School of Biomedical Sciences, University of Nottingham, under the joint supervision of Professor C.J. Hawkey and Dr A.J. Bennett. Karen Marie McCartney ii Publications & Presentations Publications Gut 2011, 60 A115-A116 Gastroenterology 2010 138 (5) S502 Gastroenterology 2009, 136 (5) A618-A619 Gastroenterology 2009, 136 (5) A752-A753 Gastroenterology 2008, 134 (4) A304 Presentations British Society of Gastroenterology 14/03/11 – 17/03/11 Birmingham NCC *Poster submitted ‘Substantial chemo-preventative effect of piroxicam in Min mice independent of peroxisome proliferator activated receptor alpha’ *Awarded poster of distinction United European Gastroenterology Week 23/10/10 – 27/10/10 Barcelona, Spain Poster submitted ‘Substantial chemo-preventative effect of piroxicam in Min mice independent of peroxisome proliferator activated receptor alpha’ Digestive Diseases Week 1/05/10 – 5/05/10 New Orleans, LA Poster submitted ‘Increased longevity in polyp-bearing mice treated with piroxicam’ European Association of Cancer Research Symposium (EACR) 3/07/09 Nottingham Poster submitted ‘The role of PPAR alpha in the effects of NSAIDs upon colon cancer’ iii Abbreviations used in this thesis AA Arachidonic acid APC Adenomatous polyposis coli ASPA Animals (Scientific Procedures) Act 1986 BLAST Basic local alignment search tool BMSU Biomedical Science Unit Cox Cyclooxygenase Cyp Cytochrome P450 FAP Familial adenomatous polyposis IPA Ingenuity pathway analysis IPKB Ingenuity Pathway Knowledge Base Lox Lipoxygenase Min Multiple intestinal neoplasia NCBI National Centre for Biotechnology Information NSAIDs Non-steroidal anti-inflammatory drugs PPAR Peroxisome proliferator activated receptor PPRE Peroxisome proliferator response element RT Q PCR Real Time Quantitative Polymerase Chain Reaction UTR Untranslated region iv Acknowledgements I would like to dedicate this research to my four children, Emma, Lisa, Zoe and Luke, and to the memory of their dad, Les. I would like to thank my two supervisors, Professor Christopher Hawkey – Chris, and Dr Andrew Bennett – Andy, for their insight, support, help and encouragement during my research and personal difficulties. I would also like to acknowledge and thank the Medical Research Council, and the School of Clinical Sciences, University of Nottingham, for funding this research. I would like to say thank you to my children for championing their mum throughout the years of my study. Thank you also to Richard, for his unswerving support - and the odd glass or two of wine! To my dad, I would like to say – I have done it! When the going got tough, I kept going. Thank you for having faith in me. A big thank you to all FRAME lab members especially Elke Gottschalg for her ‘listening ear’ and support, and Monika Owen and Nicki De Vivo, for their assistance and constructive advice in the lab. Thank you to all of the staff in the Biomedical Support Unit for their help with my mouse studies, especially Mark Trussell and Neil Yates. And thank you to Dr Emma King, Denise Christie and Ian Ward in the Advanced Microscopy Unit, for help and instruction with microscopes and staining techniques. I would like to say a special thank you for the support and compassion shown to me by the late Professor Sue Watson. Lastly, but by no means least, to my friends and colleagues in the Nottingham Digestive Diseases Centre, and especially Diane Stevenson, Jen Dumbleton and Rosemary Dainty, I would like to say thank you for being there to chat about life, music, theatre etc. etc. - anything but ‘the PhD!’ v Table of Contents Abstract ……………………………………………………………………… i Declaration ………..………………………………………………………… ii Publications & Presentations ……………………………………………... iii Abbreviations used in this thesis …………………………………………. iv Acknowledgements .………………………………………………………... v Table of Contents ………………………………………………………….. vi List of Figures …………………………………………………………........ xi List of Tables ………………………………………………………………. xv 1 Introduction..................................................................................... 1 1.1 Function, structure & histology of the small bowel & colon ...... 2 1.2 Early detection & screening for colon cancer .......................... 4 1.3 Pathogenesis of colon cancer ................................................. 5 1.4 Adenomatosis polyposis coli gene (APC gene) & the Min mouse model ..................................................................................... 8 1.4.1 Min mice as a model for Familial Adenomatous Polyposis (FAP) & colon cancer ..................................................................... 9 1.5 Metabolism of Arachidonic Acid ............................................ 11 1.6 Eicosanoid pathways in colorectal cancer development & progression ...................................................................................... 16 1.6.1 Cyclooxygenase pathway ................................................ 16 1.6.2 Lipoxygenase pathway .................................................... 18 1.6.3 Cytochrome P-450 pathway ............................................. 19 1.7 Mechanism of action of Cyclooxygenase-2 ........................... 19 1.7.1 Apoptosis ......................................................................... 19 1.7.2 Angiogenesis ................................................................... 20 1.7.3 Metastasis ........................................................................ 21 1.7.4 Immune effects ................................................................ 21 vi 1.7.5 Resolution of inflammation ............................................... 22 1.8 Cyclooxygenase inhibitors as cancer treatment & prevention 22 1.8.1 Aspirin .............................................................................. 22 1.8.2 Non-selective non-steroidal anti-inflammatory drugs (NSAIDs) ...................................................................................... 23 1.8.3 Selective cyclooxygenase 2 (Cox-2) inhibitors ................. 24 1.8.4 PPARα as a target for eicosanoids .................................. 24 1.8.5 PPARs as a target for NSAIDs......................................... 25 1.9 Peroxisome proliferator activated receptors (PPARs) ........... 25 1.10 PPARs – Role in Cancer and Inflammation ........................... 31 1.10.1 PPAR alpha (PPARα) ................................................... 31 1.10.2 PPAR beta/delta (PPARβ/δ) ......................................... 33 1.10.3 PPAR gamma (PPAR γ) ............................................... 35 1.10.4 Pan & dual-PPAR agonists ........................................... 36 1.11 Hypothesis ............................................................................ 37 1.12 Aims and Objectives .............................................................. 37 2 Materials ....................................................................................... 39 2.1 Reagents ............................................................................... 39 2.2 Protocols for preparation of working solutions & buffers ....... 41 3 The role of PPARα in malignant pathology
Load more

Recommended publications
  • S41467-020-18249-3.Pdf
    ARTICLE https://doi.org/10.1038/s41467-020-18249-3 OPEN Pharmacologically reversible zonation-dependent endothelial cell transcriptomic changes with neurodegenerative disease associations in the aged brain Lei Zhao1,2,17, Zhongqi Li 1,2,17, Joaquim S. L. Vong2,3,17, Xinyi Chen1,2, Hei-Ming Lai1,2,4,5,6, Leo Y. C. Yan1,2, Junzhe Huang1,2, Samuel K. H. Sy1,2,7, Xiaoyu Tian 8, Yu Huang 8, Ho Yin Edwin Chan5,9, Hon-Cheong So6,8, ✉ ✉ Wai-Lung Ng 10, Yamei Tang11, Wei-Jye Lin12,13, Vincent C. T. Mok1,5,6,14,15 &HoKo 1,2,4,5,6,8,14,16 1234567890():,; The molecular signatures of cells in the brain have been revealed in unprecedented detail, yet the ageing-associated genome-wide expression changes that may contribute to neurovas- cular dysfunction in neurodegenerative diseases remain elusive. Here, we report zonation- dependent transcriptomic changes in aged mouse brain endothelial cells (ECs), which pro- minently implicate altered immune/cytokine signaling in ECs of all vascular segments, and functional changes impacting the blood–brain barrier (BBB) and glucose/energy metabolism especially in capillary ECs (capECs). An overrepresentation of Alzheimer disease (AD) GWAS genes is evident among the human orthologs of the differentially expressed genes of aged capECs, while comparative analysis revealed a subset of concordantly downregulated, functionally important genes in human AD brains. Treatment with exenatide, a glucagon-like peptide-1 receptor agonist, strongly reverses aged mouse brain EC transcriptomic changes and BBB leakage, with associated attenuation of microglial priming. We thus revealed tran- scriptomic alterations underlying brain EC ageing that are complex yet pharmacologically reversible.
    [Show full text]
  • Transcriptional Regulatory Networks in Hepatitis C Virus-Induced
    www.nature.com/scientificreports OPEN Transcriptional Regulatory Networks in Hepatitis C Virus- induced Hepatocellular Carcinoma Received: 5 April 2018 Marwa Zahra1, Hassan Azzazy1,2 & Ahmed Moustafa 1,3 Accepted: 4 September 2018 Understanding the transcriptional regulatory elements that infuence the progression of liver disease Published: xx xx xxxx in the presence of hepatitis C virus (HCV) infection is critical for the development of diagnostic and therapeutic approaches. Systems biology provides a roadmap by which these elements may be integrated. In this study, a previously published dataset of 124 microarray samples was analyzed in order to determine diferentially expressed genes across four tissue types/conditions (normal, cirrhosis, cirrhosis HCC, and HCC). Diferentially expressed genes were assessed for their functional clustering and those genes were annotated with their potential transcription factors and miRNAs. Transcriptional regulatory networks were constructed for each pairwise comparison between the 4 tissue types/ conditions. Based on our analysis, it is predicted that the disruption in the regulation of transcription factors such as AP-1, PPARγ, and NF-κB could contribute to the liver progression from cirrhosis to steatosis and eventually to HCC. Whereas the condition of the liver digresses, the downregulation of miRNAs’ (such as miR-27, Let-7, and miR-106a) expression makes the transition of the liver through each pathological stage more apparent. This preliminary data can be used to guide future experimental work. An understanding of the transcriptional regulatory attributes acts as a road map to help design interference strategies in order to target the key regulators of progression of HCV induced HCC. HCV is an epidemic afecting an estimated 160 million individuals worldwide1.
    [Show full text]
  • Whole Exome Sequencing in Families at High Risk for Hodgkin Lymphoma: Identification of a Predisposing Mutation in the KDR Gene
    Hodgkin Lymphoma SUPPLEMENTARY APPENDIX Whole exome sequencing in families at high risk for Hodgkin lymphoma: identification of a predisposing mutation in the KDR gene Melissa Rotunno, 1 Mary L. McMaster, 1 Joseph Boland, 2 Sara Bass, 2 Xijun Zhang, 2 Laurie Burdett, 2 Belynda Hicks, 2 Sarangan Ravichandran, 3 Brian T. Luke, 3 Meredith Yeager, 2 Laura Fontaine, 4 Paula L. Hyland, 1 Alisa M. Goldstein, 1 NCI DCEG Cancer Sequencing Working Group, NCI DCEG Cancer Genomics Research Laboratory, Stephen J. Chanock, 5 Neil E. Caporaso, 1 Margaret A. Tucker, 6 and Lynn R. Goldin 1 1Genetic Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD; 2Cancer Genomics Research Laboratory, Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD; 3Ad - vanced Biomedical Computing Center, Leidos Biomedical Research Inc.; Frederick National Laboratory for Cancer Research, Frederick, MD; 4Westat, Inc., Rockville MD; 5Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD; and 6Human Genetics Program, Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD, USA ©2016 Ferrata Storti Foundation. This is an open-access paper. doi:10.3324/haematol.2015.135475 Received: August 19, 2015. Accepted: January 7, 2016. Pre-published: June 13, 2016. Correspondence: [email protected] Supplemental Author Information: NCI DCEG Cancer Sequencing Working Group: Mark H. Greene, Allan Hildesheim, Nan Hu, Maria Theresa Landi, Jennifer Loud, Phuong Mai, Lisa Mirabello, Lindsay Morton, Dilys Parry, Anand Pathak, Douglas R. Stewart, Philip R. Taylor, Geoffrey S. Tobias, Xiaohong R. Yang, Guoqin Yu NCI DCEG Cancer Genomics Research Laboratory: Salma Chowdhury, Michael Cullen, Casey Dagnall, Herbert Higson, Amy A.
    [Show full text]
  • Identification of Differentially Expressed Genes in Human Bladder Cancer Through Genome-Wide Gene Expression Profiling
    521-531 24/7/06 18:28 Page 521 ONCOLOGY REPORTS 16: 521-531, 2006 521 Identification of differentially expressed genes in human bladder cancer through genome-wide gene expression profiling KAZUMORI KAWAKAMI1,3, HIDEKI ENOKIDA1, TOKUSHI TACHIWADA1, TAKENARI GOTANDA1, KENGO TSUNEYOSHI1, HIROYUKI KUBO1, KENRYU NISHIYAMA1, MASAKI TAKIGUCHI2, MASAYUKI NAKAGAWA1 and NAOHIKO SEKI3 1Department of Urology, Graduate School of Medical and Dental Sciences, Kagoshima University, 8-35-1 Sakuragaoka, Kagoshima 890-8520; Departments of 2Biochemistry and Genetics, and 3Functional Genomics, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, Japan Received February 15, 2006; Accepted April 27, 2006 Abstract. Large-scale gene expression profiling is an effective CKS2 gene not only as a potential biomarker for diagnosing, strategy for understanding the progression of bladder cancer but also for staging human BC. This is the first report (BC). The aim of this study was to identify genes that are demonstrating that CKS2 expression is strongly correlated expressed differently in the course of BC progression and to with the progression of human BC. establish new biomarkers for BC. Specimens from 21 patients with pathologically confirmed superficial (n=10) or Introduction invasive (n=11) BC and 4 normal bladder samples were studied; samples from 14 of the 21 BC samples were subjected Bladder cancer (BC) is among the 5 most common to microarray analysis. The validity of the microarray results malignancies worldwide, and the 2nd most common tumor of was verified by real-time RT-PCR. Of the 136 up-regulated the genitourinary tract and the 2nd most common cause of genes we detected, 21 were present in all 14 BCs examined death in patients with cancer of the urinary tract (1-7).
    [Show full text]
  • Supplementary Data
    Supplementary Fig. 1 A B Responder_Xenograft_ Responder_Xenograft_ NON- NON- Lu7336, Vehicle vs Lu7466, Vehicle vs Responder_Xenograft_ Responder_Xenograft_ Sagopilone, Welch- Sagopilone, Welch- Lu7187, Vehicle vs Lu7406, Vehicle vs Test: 638 Test: 600 Sagopilone, Welch- Sagopilone, Welch- Test: 468 Test: 482 Responder_Xenograft_ NON- Lu7860, Vehicle vs Responder_Xenograft_ Sagopilone, Welch - Lu7558, Vehicle vs Test: 605 Sagopilone, Welch- Test: 333 Supplementary Fig. 2 Supplementary Fig. 3 Supplementary Figure S1. Venn diagrams comparing probe sets regulated by Sagopilone treatment (10mg/kg for 24h) between individual models (Welsh Test ellipse p-value<0.001 or 5-fold change). A Sagopilone responder models, B Sagopilone non-responder models. Supplementary Figure S2. Pathway analysis of genes regulated by Sagopilone treatment in responder xenograft models 24h after Sagopilone treatment by GeneGo Metacore; the most significant pathway map representing cell cycle/spindle assembly and chromosome separation is shown, genes upregulated by Sagopilone treatment are marked with red thermometers. Supplementary Figure S3. GeneGo Metacore pathway analysis of genes differentially expressed between Sagopilone Responder and Non-Responder models displaying –log(p-Values) of most significant pathway maps. Supplementary Tables Supplementary Table 1. Response and activity in 22 non-small-cell lung cancer (NSCLC) xenograft models after treatment with Sagopilone and other cytotoxic agents commonly used in the management of NSCLC Tumor Model Response type
    [Show full text]
  • Molecular Correlates of Metastasis by Systematic Pan-Cancer Analysis Across the Cancer Genome Atlas
    Author Manuscript Published OnlineFirst on November 6, 2018; DOI: 10.1158/1541-7786.MCR-18-0601 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Molecular correlates of metastasis by systematic pan-cancer analysis across The Cancer Genome Atlas Fengju Chen1*, Yiqun Zhang1*, Sooryanarayana Varambally2,3, Chad J. Creighton1,4,5,6 1. Dan L. Duncan Comprehensive Cancer Center Division of Biostatistics, Baylor College of Medicine, Houston, TX, USA. 2. Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL 35233, USA 3. Molecular and Cellular Pathology, Department of Pathology, University of Alabama at Birmingham, Birmingham, AL 35233, USA 4. Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA 5. Human Genome Sequencing Center, Baylor College of Medicine, Houston, TX 77030, USA 6. Department of Medicine, Baylor College of Medicine, Houston, TX, USA * co-first authors Running title: Pan-cancer metastasis correlates Abbreviations: TCGA, The Cancer Genome Atlas; RNA-seq, RNA sequencing; RPPA, reverse- phase protein arrays Correspondence to: Chad J. Creighton ([email protected]) One Baylor Plaza, MS305 Houston, TX 77030 Disclosure of potential conflicts of interest: The authors have no conflicts of interest. 1 Downloaded from mcr.aacrjournals.org on September 28, 2021. © 2018 American Association for Cancer Research. Author Manuscript Published OnlineFirst on November 6, 2018; DOI: 10.1158/1541-7786.MCR-18-0601 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Abstract Tumor metastasis is a major contributor to cancer patient mortality, but the process remains poorly understood.
    [Show full text]
  • Characterizing Genomic Duplication in Autism Spectrum Disorder by Edward James Higginbotham a Thesis Submitted in Conformity
    Characterizing Genomic Duplication in Autism Spectrum Disorder by Edward James Higginbotham A thesis submitted in conformity with the requirements for the degree of Master of Science Graduate Department of Molecular Genetics University of Toronto © Copyright by Edward James Higginbotham 2020 i Abstract Characterizing Genomic Duplication in Autism Spectrum Disorder Edward James Higginbotham Master of Science Graduate Department of Molecular Genetics University of Toronto 2020 Duplication, the gain of additional copies of genomic material relative to its ancestral diploid state is yet to achieve full appreciation for its role in human traits and disease. Challenges include accurately genotyping, annotating, and characterizing the properties of duplications, and resolving duplication mechanisms. Whole genome sequencing, in principle, should enable accurate detection of duplications in a single experiment. This thesis makes use of the technology to catalogue disease relevant duplications in the genomes of 2,739 individuals with Autism Spectrum Disorder (ASD) who enrolled in the Autism Speaks MSSNG Project. Fine-mapping the breakpoint junctions of 259 ASD-relevant duplications identified 34 (13.1%) variants with complex genomic structures as well as tandem (193/259, 74.5%) and NAHR- mediated (6/259, 2.3%) duplications. As whole genome sequencing-based studies expand in scale and reach, a continued focus on generating high-quality, standardized duplication data will be prerequisite to addressing their associated biological mechanisms. ii Acknowledgements I thank Dr. Stephen Scherer for his leadership par excellence, his generosity, and for giving me a chance. I am grateful for his investment and the opportunities afforded me, from which I have learned and benefited. I would next thank Drs.
    [Show full text]
  • Canine Polydactyl Mutations with Heterogeneous Origin in the Conserved Intronic Sequence of LMBR1 Kiyun Park*, Joohyun Kang*, Kr
    Genetics: Published Articles Ahead of Print, published on August 9, 2008 as 10.1534/genetics.108.087114 Canine polydactyl mutations with heterogeneous origin in the conserved intronic sequence of LMBR1 Kiyun Park*, Joohyun Kang*, Krishna Pd. Subedi*, Ji-Hong Ha†, and Chankyu Park*1 * Department of Biological Sciences, Korea Advanced Institute of Science and Technology, Yuseong-gu, Daejon 305-701, Republic of Korea †Department of Genetic Engineering, College of Natural Sciences, Kyungpook National University,1370 Sankyuk-dong, Daegu 702-701, Republic of Korea 1 Running title: LMBR1 and canine polydactyly Keywords: Polydactyly; canine breed; linkage analysis; C7orf2/LMBR1; multi-species conserved sequence 1Corresponding author: Chankyu Park Department of Biological Sciences, Korea Advanced Institute of Science and Technology, Yuseong- gu, Daejon 305-701, Republic of Korea.E-mail: [email protected], Phone: 82-42-869-2629 2 ABSTRACT Canine preaxial polydactyly (PPD) in the hind limb is a developmental trait that restores the first digit lost during canine evolution. Using a linkage analysis, we demonstrated previously that the affected gene in a Korean breed is located on canine chromosome 16. The candidate locus was further limited to a linkage disequilibrium (LD) block of less than 213 kb comprising the single gene, LMBR1, by LD mapping with single-nucleotide polymorphisms (SNPs) for affected individuals from both Korean and Western breeds. The ZPA regulatory sequence (ZRS) in intron 5 of LMBR1 was implicated in mammalian polydactyly. An analysis of the LD haplotypes around the ZRS for various dog breeds revealed that only a subset is assigned to Western breeds. Furthermore, two distinct affected haplotypes for Asian and Western breeds were found, each containing different single-base changes in the upstream sequence (pZRS) of the ZRS.
    [Show full text]
  • Molecular Targeting and Enhancing Anticancer Efficacy of Oncolytic HSV-1 to Midkine Expressing Tumors
    University of Cincinnati Date: 12/20/2010 I, Arturo R Maldonado , hereby submit this original work as part of the requirements for the degree of Doctor of Philosophy in Developmental Biology. It is entitled: Molecular Targeting and Enhancing Anticancer Efficacy of Oncolytic HSV-1 to Midkine Expressing Tumors Student's name: Arturo R Maldonado This work and its defense approved by: Committee chair: Jeffrey Whitsett Committee member: Timothy Crombleholme, MD Committee member: Dan Wiginton, PhD Committee member: Rhonda Cardin, PhD Committee member: Tim Cripe 1297 Last Printed:1/11/2011 Document Of Defense Form Molecular Targeting and Enhancing Anticancer Efficacy of Oncolytic HSV-1 to Midkine Expressing Tumors A dissertation submitted to the Graduate School of the University of Cincinnati College of Medicine in partial fulfillment of the requirements for the degree of DOCTORATE OF PHILOSOPHY (PH.D.) in the Division of Molecular & Developmental Biology 2010 By Arturo Rafael Maldonado B.A., University of Miami, Coral Gables, Florida June 1993 M.D., New Jersey Medical School, Newark, New Jersey June 1999 Committee Chair: Jeffrey A. Whitsett, M.D. Advisor: Timothy M. Crombleholme, M.D. Timothy P. Cripe, M.D. Ph.D. Dan Wiginton, Ph.D. Rhonda D. Cardin, Ph.D. ABSTRACT Since 1999, cancer has surpassed heart disease as the number one cause of death in the US for people under the age of 85. Malignant Peripheral Nerve Sheath Tumor (MPNST), a common malignancy in patients with Neurofibromatosis, and colorectal cancer are midkine- producing tumors with high mortality rates. In vitro and preclinical xenograft models of MPNST were utilized in this dissertation to study the role of midkine (MDK), a tumor-specific gene over- expressed in these tumors and to test the efficacy of a MDK-transcriptionally targeted oncolytic HSV-1 (oHSV).
    [Show full text]
  • Itm2aexpands Evidence for Genetic and Environmental Interaction In
    CLINICAL RESEARCH ARTICLE ITM2A Expands Evidence for Genetic and Environmental Interaction in Graves Disease Pathogenesis Xiao-Ping Ye,1,2* Fei-Fei Yuan,1,2* Le-Le Zhang,2* Yu-Ru Ma,2 Man-Man Zhang,2 Wei Liu,2 Feng Sun,2 Jing Wu,2 Meng Lu,2 Li-Qiong Xue,2 Jing-Yi Shi,1 Shuang-Xia Zhao,2 Huai-Dong Song,1,2 Jun Liang3,4 and Cui-Xia Zheng,2 for The China Consortium for the Genetics of Autoimmune Thyroid Disease Downloaded from https://academic.oup.com/jcem/article/102/2/652/2972067 by guest on 27 September 2021 1State Key Laboratory of Medical Genomics, Shanghai Institute of Endocrinology and Metabolism, Ruijin Hospital affiliated to Shanghai Jiaotong University School of Medicine, Shanghai 200025, China; 2Research Center for Clinical Medicine, Department of Respiration and Endocrinology, The Ninth People’s Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai 200011, China; 3Department of Endocrinology, The Central Hospital of Xuzhou Affiliated to Xuzhou Medical College, Xuzhou, Jiangsu Province 221109, China; and 4Xuzhou Clinical School of Xuzhou Medical College, The Affiliated XuZhou Hospital of Medical College of Southeast University, Xuzhou, Jiangsu Province 221009, China Context: Graves disease (GD) is a common autoimmune disease triggered by genetic predisposition and environmental factors. However, the mechanisms of interaction between genetic and envi- ronmental factors contributing to the development of GD remain unknown. Objective: We aimed to identify GD susceptibility variants and genes on Xq21.1 locus and interpret the contribution of interaction between genetic predisposition on Xq21.1 and environmental factors to GD.
    [Show full text]
  • A 1.35 Mb DNA Fragment Is Inserted Into the DHMN1 Locus on Chromosome 7Q34–Q36.2
    Hum Genet (2016) 135:1269–1278 DOI 10.1007/s00439-016-1720-4 ORIGINAL INVESTIGATION A 1.35 Mb DNA fragment is inserted into the DHMN1 locus on chromosome 7q34–q36.2 Alexander P. Drew1 · Anthony N. Cutrupi1,3 · Megan H. Brewer1,3 · Garth A. Nicholson1,2,3 · Marina L. Kennerson1,2,3 Received: 5 April 2016 / Accepted: 25 July 2016 / Published online: 3 August 2016 © Springer-Verlag Berlin Heidelberg 2016 Abstract Distal hereditary motor neuropathies predomi- for hereditary motor neuropathies and highlights the grow- nantly affect the motor neurons of the peripheral nervous ing importance of interrogating the non-coding genome for system leading to chronic disability. Using whole genome SV mutations in families which have been excluded for sequencing (WGS) we have identified a novel structural genome wide coding mutations. variation (SV) within the distal hereditary motor neuropa- thy locus on chromosome 7q34–q36.2 (DHMN1). The SV involves the insertion of a 1.35 Mb DNA fragment Introduction into the DHMN1 disease locus. The source of the inserted sequence is 2.3 Mb distal to the disease locus at chromo- The distal hereditary motor neuropathies (dHMN) are a some 7q36.3. The insertion involves the duplication of five group of progressive neurodegenerative disorders that pri- genes (LOC389602, RNF32, LMBR1, NOM1, MNX1) and marily affect the motor neurons of distal limbs without partial duplication of UBE3C. The genomic structure of affecting sensory neurons. The disorder is a length depend- genes within the DHMN1 locus are not disrupted by the ant neuropathy in which the longest nerves are initially insertion and no disease causing point mutations within affected.
    [Show full text]
  • Mapping the Shh Long-Range Regulatory Domain
    Edinburgh Research Explorer Mapping the Shh long-range regulatory domain Citation for published version: Anderson, E, Devenney, PS, Hill, RE & Lettice, LA 2014, 'Mapping the Shh long-range regulatory domain', Development, vol. 141, no. 20, pp. 3934-3943. https://doi.org/10.1242/dev.108480 Digital Object Identifier (DOI): 10.1242/dev.108480 Link: Link to publication record in Edinburgh Research Explorer Document Version: Publisher's PDF, also known as Version of record Published In: Development Publisher Rights Statement: This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution and reproduction in any medium provided that the original work is properly attributed. General rights Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights. Take down policy The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact [email protected] providing details, and we will remove access to the work immediately and investigate your claim. Download date: 04. Oct. 2021 Development ePress. Posted online 24 September 2014 © 2014. Published by The Company of Biologists Ltd | Development (2014) 141, 1-10 doi:10.1242/dev.108480 RESEARCH ARTICLE Mapping the Shh long-range regulatory domain Eve Anderson, Paul S.
    [Show full text]